SCHEMBL1699050

SCHEMBL1699050

c1ccc2nc(N[C@@H]3CCCC[C@H]3Nc3ccc4ccccc4n3)ccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.58
RAB9A P51151 5/20 0.58
NCF1 P14598 1/20 0.55
DDB1 Q16531 1/20 0.52
CRBN Q96SW2 1/20 0.52
HCRTR1 O43613 1/20 0.48
HCRTR2 O43614 1/20 0.48
MCHR1 Q99705 1/20 0.46
HRH3 Q9Y5N1 1/20 0.43
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 1/20 0.42
USP30 Q70CQ3 1/20 0.42
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PDE10A Q9Y233 3/20 0.41
SSTR3 P32745 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1708932 1.00 NPC1 (0.58) NPC1RAB9ANCF1DDB1CRBN
SCHEMBL16666168 0.87 NPC1 (0.56) NPC1RAB9ANCF1DDB1CRBN
SCHEMBL9056686 0.86 NPC1 (0.59) NPC1RAB9ANCF1DDB1CRBN
Hydrochloric Acid SCHEMBL8852766 0.84 NPC1 (0.57) NPC1RAB9ANCF1DDB1CRBN
SCHEMBL24092000 0.84 MCHR1 (0.57) NPC1RAB9ANCF1DDB1CRBN
SCHEMBL29911218 0.84 MCHR1 (0.57) NPC1RAB9ANCF1DDB1CRBN
SCHEMBL31620776 0.83 NCF1 (0.57) NPC1RAB9ANCF1DDB1CRBN
SCHEMBL1708938 0.81 NPC1 (0.42) NPC1RAB9ANCF1DDB1CRBN
SCHEMBL1699014 0.81 NPC1 (0.42) NPC1RAB9ANCF1DDB1CRBN
SCHEMBL12723436 0.81 NPC1 (0.50) NPC1RAB9ANCF1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9399652-B2 Synthetic route to pactamycin and pactamycin analogs THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2016-07-26 US disclosed
US-9399652-B2 Synthetic route to pactamycin and pactamycin analogs THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2016-07-26 US disclosed
US-20150329570-A1 SYNTHETIC ROUTE TO PACTAMYCIN AND PACTAMYCIN ANALOGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-19 US disclosed
US-20150329570-A1 SYNTHETIC ROUTE TO PACTAMYCIN AND PACTAMYCIN ANALOGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-19 US disclosed
US-8889863-B2 Stereoselective methods, catalysts and intermediates for the synthesis of (−)-Nutlin-3 and related compounds VANDERBILT UNIVERSITY (US) 2014-11-18 US disclosed
US-8889863-B2 Stereoselective methods, catalysts and intermediates for the synthesis of (−)-Nutlin-3 and related compounds VANDERBILT UNIVERSITY (US) 2014-11-18 US disclosed
US-20120088915-A1 STEREOSELECTIVE METHODS, CATALYSTS AND INTERMEDIATES FOR THE SYNTHESIS OF (-)-NUTLIN-3 AND RELATED COMPOUNDS VANDERBILT UNIVERSITY 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329570-A1 SYNTHETIC ROUTE TO PACTAMYCIN AND PACTAMYCIN ANALOGS PAICS, DPM1, MANBA NPC1 3126/4885RAB9A 1256/4885NCF1 2477/4885
US-20120088915-A1 STEREOSELECTIVE METHODS, CATALYSTS AND INTERMEDIATES FOR THE SYNTHESIS OF (-)-NUTLIN-3 AND RELATED COMPOUNDS NUTF2, MDM2, CIAPIN1 NPC1 2645/4885RAB9A 3389/4885NCF1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.